TRI-611, a selective, brain-penetrant molecular glue degrader of ALK
Ranking
Overall
70
Content
80
Popularity
47
Observed public metrics from 1 member.
Merged summary
TL;DR - TRI-611 is a selective, brain-penetrant molecular glue degrader that targets ALK fusion proteins. Its preclinical anti-tumour activity suggests a potential new treatment strategy for ALK-positive non-small-cell lung cancer.
- TRI-611 induces ALK fusion protein degradation through a previously undescribed CRBN recruitment motif.
- Brain penetration could be relevant to treating ALK-positive cancers involving the central nervous system.
- The reported efficacy is preclinical, so clinical safety and effectiveness remain unestablished.
Sources (1)
TRI-611, a selective, brain-penetrant molecular glue degrader of ALK
Public signals
OpenAlex citations 0
TL;DR - TRI-611 is a selective, brain-penetrant molecular glue degrader that targets ALK fusion proteins. Its preclinical anti-tumour activity suggests a potential new treatment strategy for ALK-positive non-small-cell lung cancer.
- TRI-611 induces ALK fusion protein degradation through a previously undescribed CRBN recruitment motif.
- Brain penetration could be relevant to treating ALK-positive cancers involving the central nervous system.
- The reported efficacy is preclinical, so clinical safety and effectiveness remain unestablished.